EXPERTISE. RELATIONSHIPS. CAPITAL.

Hopen Life Science Ventures invests in exceptional early-to mid-stage life science opportunities. We are very active in the Midwest, a market traditionally under-served with capital.  Our team consists of professionals with extensive senior leadership experience in public and private life science companies.  We apply our scientific and business insights along with a proven resource network to enhance the development of our portfolio companies.

Hopen manages over $65 million between its two funds.

In 2011, Hopen began investing from Hopen Life Science Fund II, LP.  The fund’s strategy focuses on early-to-mid stage devices, diagnostics, therapeutics and healthcare information technology.  Geographically, the focus is on the Midwest, but the fund will invest nationally in exceptional opportunities.

Hopen Fund I invested in a portfolio of seven companies, including three focused on drug development, two medical devices, one on health care information technology, and one on drug discovery enabling technology.  These companies have raised over $115 million of total syndicated investment.